Despite the enormous success of immune-checkpoint blockade in tumor immunotherapy, the application of immune checkpoint inhibitor (ICI) in lung cancer is obscure since this treatment is only recommended to the advanced NSCLC patients without mutation in oncogenes such as EGFR and ALK. Emerging studies indicate the poor clinical outcomes of ICI treatment for patients with oncogenic mutations except for KRAS. For these patients, there is a high risk of relapse after targeted therapy as the first- or second-line treatment. They are usually excluded from the clinical trials of ICI treatment, which even further worsens the situation, leaving few options for the clinician. It is very urgent to study the roles of immunotherapy, such as ICI, with the combination of other therapies, in these patients.
To develop an efficient and precise treatment for these patients, several mysteries need to be solved, including how the oncogenic mutants affect the “cold” or “hot” tumor microenvironment, the outcome of immunotherapy since patients with KRAS-mutation respond better to ICI treatment than others, and what is the best way to design the combination of immunotherapy with other traditional therapies. To this end, the identification of biomarkers is also in great need.
The aim of this Research Topic is to provide a comprehensive overview of our current and developing knowledge of immunotherapy in NSCLC patients with oncogenic mutations, to clinicians and basic researchers in tumor immunology field as well as personnels in the pharmacological industry. In this Research Topic, we will explore the optimized immunotherapy modality in front- or later-line settings. Secondly, we encourage the investigation and discovery of biomarkers related to the status of immune response in tumor microenvironment. Last but not least, we aim to further the understanding of the mechanisms governing the immune responses in these patients.
We expect the Original Research, Case Reports, and Review articles on the following (but not limited to) aspects of the immunotherapy for advanced NSCLC with oncogenic mutations:
1. New therapeutic exploration
2. The immunotherapy in classical or specific subgroups
3. Biomarkers for response (include HPD), toxicities and so on
4. Strategies for personalized and precise immunotherapy based on the oncogenic mutations.
5. irAEs in the immunotherapy for advanced NSCLC with oncogenic mutations.
6. Changes in TME related to immunotherapy.
Please Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Despite the enormous success of immune-checkpoint blockade in tumor immunotherapy, the application of immune checkpoint inhibitor (ICI) in lung cancer is obscure since this treatment is only recommended to the advanced NSCLC patients without mutation in oncogenes such as EGFR and ALK. Emerging studies indicate the poor clinical outcomes of ICI treatment for patients with oncogenic mutations except for KRAS. For these patients, there is a high risk of relapse after targeted therapy as the first- or second-line treatment. They are usually excluded from the clinical trials of ICI treatment, which even further worsens the situation, leaving few options for the clinician. It is very urgent to study the roles of immunotherapy, such as ICI, with the combination of other therapies, in these patients.
To develop an efficient and precise treatment for these patients, several mysteries need to be solved, including how the oncogenic mutants affect the “cold” or “hot” tumor microenvironment, the outcome of immunotherapy since patients with KRAS-mutation respond better to ICI treatment than others, and what is the best way to design the combination of immunotherapy with other traditional therapies. To this end, the identification of biomarkers is also in great need.
The aim of this Research Topic is to provide a comprehensive overview of our current and developing knowledge of immunotherapy in NSCLC patients with oncogenic mutations, to clinicians and basic researchers in tumor immunology field as well as personnels in the pharmacological industry. In this Research Topic, we will explore the optimized immunotherapy modality in front- or later-line settings. Secondly, we encourage the investigation and discovery of biomarkers related to the status of immune response in tumor microenvironment. Last but not least, we aim to further the understanding of the mechanisms governing the immune responses in these patients.
We expect the Original Research, Case Reports, and Review articles on the following (but not limited to) aspects of the immunotherapy for advanced NSCLC with oncogenic mutations:
1. New therapeutic exploration
2. The immunotherapy in classical or specific subgroups
3. Biomarkers for response (include HPD), toxicities and so on
4. Strategies for personalized and precise immunotherapy based on the oncogenic mutations.
5. irAEs in the immunotherapy for advanced NSCLC with oncogenic mutations.
6. Changes in TME related to immunotherapy.
Please Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
